Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].

Zhonghua yi xue za zhi - 17 Nov 2004

Cui Jun-chang, Liu You-ning, Wang Rui, Liang Bei-bei, Pei Fei, Zheng Zhuan-jie

Abstract excerpt

OBJECTIVE: To establish a method to measure mutant prevention concentration (MPC) in vitro, and to measure MPC of fluoroquinolones for staphylococcus aureus. METHODS: The staphylococcus aureus strain ATCC25923 and 20 ciprofloxacin-susceptible clinical isolates were enriched in broth, and the bacterial concentrations were adjusted to 10(10) colony forming units per milliliter. The minimal inhibitory concentration...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Infective Agents
Share to Culture Media
Share to Drug Resistance, Bacterial

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Fluoroquinolones

Share to Microbial Sensitivity Tests

Share to Mutation

Share to Staphylococcus aureus

Source

Identifiers

PMID: 15631794

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].PMID 15631794Read ↗

[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].Semantic proximity Read ↗

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.Semantic proximity Read ↗

Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.Semantic proximity Read ↗

[Resistant mutant prevention concentration of fluoroquinolones in clinical isolates of extended spectrum beta-lactamase (ESBL) producing and non-producing strains of Escherichia coli].Semantic proximity Read ↗

[The concentrations of fluoroquinolones in prevention of Staphylococcus epidermidis from mutant in ocular surface].Semantic proximity Read ↗

[Mutant prevention concentrations of antibacterial agents to ocular pathogenic bacteria].Semantic proximity Read ↗

Mutant prevention concentrations of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumoniae.Semantic proximity Read ↗

Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.Semantic proximity Read ↗

Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.Semantic proximity Read ↗

Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.Semantic proximity Read ↗

Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.Semantic proximity Read ↗

New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.